Evidence supporting the use of: EGCG
For the health condition: Leukemia

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Epigallocatechin gallate (EGCG), the main polyphenol in green tea, has been investigated for its potential anti-cancer properties, including for leukemia. Preclinical studies have demonstrated that EGCG can induce apoptosis (programmed cell death), inhibit proliferation, and disrupt cell signaling pathways in various leukemia cell lines, such as chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). For example, EGCG has been shown to inhibit the activity of Bcl-2, induce caspase activation, and modulate signaling pathways like PI3K/Akt and NF-κB, which are important for cancer cell survival and proliferation.

Some early-phase clinical studies have explored EGCG's effects in leukemia patients, especially in CLL. A few small clinical trials have reported that EGCG (often in the form of green tea extracts) may reduce lymphocyte counts or slow disease progression in early-stage CLL, but the effects are generally modest and not sufficient to recommend EGCG as a stand-alone therapy.

Overall, while there is scientific rationale and preliminary evidence from laboratory and limited clinical studies, the evidence is still insufficient (rated 2/5) to support EGCG as a validated treatment for leukemia. EGCG is not part of standard leukemia therapy, and its use should be considered only as a complementary approach, ideally under medical supervision. Larger, robust clinical trials are needed to determine its true efficacy and safety.

More about EGCG
More about Leukemia

Products containing EGCG

We currently have no products on Vitabase that contain this ingredient.